BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05226507 (NXP800 in ADRI1a-mutated ovarian cancer): BVCT ex-ante prediction vs. reported outcome

On 8 Dec 2023, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 14 Nov 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant yet weak and commercially insufficient.

Clinical Trial

NCTID
NCT05226507
Drug Name
NXP800
Drug MoA
anti-HSF1 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
ADRI1a-mutated ovarian cancer
Human Patients
61
Sponsor
Nuvectis Pharma
Phase
Phase 1

Prediction of , index 1371

Prospective Prediction
Prediction Index
1371
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
342 days in advance
Readout Data Interpretation
NXP800 achieved at most 9% ORR (1/11 unconfirmed); which is non-superior to the 8-13% ORR by nivolumab or PLD/GEM (Journal of Clinical Oncology DOI- 10.1200/JCO.21.00334)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant yet weak and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Phase
Phase 1
Status
Terminated
Enrollment
45
Lead sponsor
Nuvectis Pharma, Inc.
Conditions
Advanced Solid Tumor; Ovarian Cancer; Ovarian Clear Cell Carcinoma; Ovarian Clear Cell Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Endometrioid Tumor; ARID1A Gene Mutation
Interventions
DRUG: NXP800
Design
Non randomized · Sequential · None
Primary purpose
Treatment
Start
2021-12-31
Primary completion
2025-01-01
Completion
2025-01-01
Primary outcomes
  • Part A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities (Day 28)
  • Part B: Estimates of disease response by RECIST v 1.1 (Baseline to 30 days post last dose of NXP800)
  • Part B: Number of patients with treatment related adverse events, and/or clinical laboratory abnormalities. (Baseline to 30 days post last dose of NXP800)

NCT05226507 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials